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INTRODUCTION
Left main (LM) stenosis is visualised in around 3-5% of
all coronary angiograms.1 A stenosis of more than 50%
of the LM is associated with significant mortality as a
critical LM lesion jeopardises at least 75% of the myo-
cardium.2 The mainstay of treatment of left main stenosis
has been coronary artery bypass grafting (CABG) with
favourable outcomes reported in various studies.3-6
Since the inception of percutaneous coronary inter-
vention (PCI), multiple attempts have been made over
the years to prove the equivalence of PCI to bypass
surgery for treating left main interventions. Early
attempts at LM PCI with plain old balloon angioplasty
(POBA) and bare metal stents showed appalling
results.7,8
Recently, data regarding LM PCI with newer generation
drug eluting stents (DES) has emerged from all parts of
the world and reviews suggest that in patients with
severe LM disease, PCI with newer generation DES is
comparable to CABG, and it offers an effective method
of revascularisation with comparable long-term rates of
major adverse outcomes.9-12 However, there is a dearth
of data on clinical outcomes of left main PCI in Pakistan.
This study is an effort to bridge this gap and put forward
our experience of LM-PCI practice at a tertiary health
care centre in Pakistan.
The primary objective of this study was to determine the
outcomes of LM PCI, both in hospital and post-discharge,
in terms of mortality. The secondary objective of the study
was to document angina, myocardial Infarction, repeat
revascularisation, stroke and heart failure in patients
who underwent LM PCI over an extended period of
follow-up.
METHODOLOGY
The study was conducted at the Aga Khan University
Hospital (AKUH), Karachi, from February till July 2016 after
approval from the hospital Ethics Review Committee.
The study included all adult patients aged 18 years or
more who underwent percutaneous LMCA revascularisation
at The Aga Khan University Hospital (AKUH), Karachi in
the last decade from April 2006 till April 2015.
For the purpose of study, patients who had undergone left
main coronary artery (LMCA) revascularisation percutan-
eously were identified using records from the AKUH
cardiology catherisation laboratory records. Information
relevant to study objectives were collected using a
predesigned proforma. Information regarding procedural
details, mortality and morbidity were collected from
review of charts or via phone follow-up after seeking
informed consent from the patients.
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ABSTRACT
Objective: To study the outcomes of left main percutaneous coronary artery (LMCA) revascularisation.
Study Design: A descriptive study.
Place and Duration of Study: The Aga Khan University Hospital (AKUH), Karachi, from February till July 2016. 
Methodology: The study included all adult patients aged 18 years or more, who underwent percutaneous LMCA
revascularisation at study centre from April 2006 till April 2015. In-hospital outcomes were ascertained of patients via
charts along with telephonic follow-up for outcome ascertainment at 1-year and 5-year. Results were expressed in terms
of means and standard deviation for quantitative variables and percentages for qualitative variables.
Results: Of the 86 patients, the mean age was 66.05 ±12.6 years and 69% (59 cases, n=86) of them were males. Sixteen
(18.6%) patients presented with cardiogenic shock and 17.4% (15 cases, n=86) required mechanical ventilation upon
arrival. Among the 86 patients, 23.3% (20 patients, n=86) underwent PCI because of unstable condition for CABG and
refusal by the surgeons. Mean follow up time for participants was 40.5 ±25.7 months with mean length of hospital stay of
4.36 ±2.4 days. In-hospital mortality was 12.8%, while mortality at 1-year and at mean follow-up was 7.3% and 6.9%,
respectively.
Conclusion: LM percutaneous coronary intervention is a viable option for patients who are hemodynamicaly unstable and
require urgent revascularisation or for patients denying bypass surgery due to other reasons in Pakistan. Prospective
studies in future may be required to evaluate the role of PCI for LM lesions in elective setting in contrast to existing
treatment options.
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The data were analysed using SPSS version 20.0 and
results were expressed in terms of means and standard
deviation for quantitative variables and frequency along
with percentages for qualitative variables.
RESULTS
A total of 86 patients underwent LM PCI at the study
centre during the studied period. Amongst patients under-
going LM PCI, 62 (72%) had unprotected LM. The most
common presentation of patients undergoing LM PCI
was unstable angina [40 patients (46.5%)], 82 (95.3%)
had native LM disease requiring PCI of LM, whereas
4.7% cases (4 patients) underwent LM PCI as a bailout
procedure. Mean follow-up duration was 40.5 ±25.7
months.
Surgical opinion by cardiothoracic surgeon for CABG
was sought for all patients prior to PCI. 23.3% (20 cases)
patients were considered unfit for CABG because of
hemodynamic instability, coexisting comorbidities,
extremes of age or due to very high surgical risks. LM
PCI was opted over CABG by patient or family in (76.7%
cases, 66 patients). LM PCI was primarily performed by
the femoral route in 94% patients (80 cases). 79% (68
cases) had distal LM PCI done and 81% (70 cases)
required PCI to other vessels in addition to LM. The
Baseline characteristics of patients are given in Table I
and procedural details of PCI are given in Table II.
The mortality at mean follow-up was 29% (25 patients),
with the mean time to death of 20.12 ±27.9 months. As
autopsy was not performed in any case, all mortalities
were presumed to be due to cardiovascular cause.
The in-hospital mortality was 12.8% (11 patients) with a
mean hospital stay of 4.36 ±2.4 days. All these patients
had unprotected LM PCI. The mean age was 69.7 ±11.3
years. Nine patients had been deemed unfit for CABG
due to hemodynamic instability as they were in
cardiogenic shock requiring intubation, inotropic support
and counter pulsation therapy with intra-aortic balloon
pump. The major cause of in-hospital mortality was
refractory cardiogenic shock (5 patients), other causes
included overwhelming sepsis and GI bleeding. Among
the 75 patients that were discharged from the hospital,
the mortality at one year was 6.6% (5 patients).
Distal LM stenting poses a unique challenge as it is
equivalent to bifurcation stenting. In this study, 68
patients (79.1%) underwent PCI to distal LM. The total
mortality for distal LM PCI at mean follow-up was 23.2%
(20 patients). The in-hospital mortality of patients
undergoing distal LM PCI was 10.4% (09 patients). 4.6%
(04 patients) undergoing distal LM PCI required target
lesion revascularisation, whereas no patient undergoing
PCI to LM ostium or shaft required TLR.
IVUS was performed in 30 patients (34.9% cases)
undergoing LM PCI, on follow-up 7 (8.13%) mortalities
were identified. Nineteen (22.09%) cases, who
underwent IVUS at the time of LM PCI, were alive at
follow-up, whereas 4 cases were lost to follow-up.
At mean follow-up from index procedure, 10 (11.6%)
patients had MI, 4 (4.6%) patients required repeat target
lesion revascularisation, and 7 (8.13%) patients had
congestive heart failure. No patient had stroke. All
patients alive at mean follow-up were compliant to dual
antiplatelet therapy with aspirin and clopidogrel.
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Table I: Baseline characteristics of the LM PCI patients.
Baseline characteristics N (%)
No. of patients 86
Age (years) 66.05 ±12.6
Male 59 (68.6)
Unprotected LM 62 (72.1)
Risk factors
Hypertension 79 (91.8)
Dyslipidemia 42 (48.8)
Diabetes 53 (61.3)
Smoking 28 (32.6)
CKD 14 (16.3)
On Hemodialysis 6 (7.0)
LV Dysfunction 42 (48.8)
Presentation
STEMI 16 (18.6)
NSTEMI 30 (34.9)
Angina 40 (46.5)
Cardiogenic shock 16 (18.6)
Intubated patients 15 (17.4)
Cardiac arrest 8 (9.3)
CKD: Chronic kidney disease;   LV dysfunction: EF <40% at the time of PCI; STEMI: ST
elevation myocardial infarction; NSTEMI: Non ST elevation myocardial infarction.
Table II: Procedure details of LM-PCI.
Procedure details N (%)
Emergent PCI 22 (25.6)
PCI of other vessels along with LM 70 (81.4)
Type of stent in LM
Drug eluting stents 71 (82.6)
Bare metal stents 13 (15.1)
Covered stent 1 (1.2)
Drug eluting balloon 1 (1.2)
Complications during PCI
Dissection 15 (17.4)
No reflow 3 (3.5)
Distal LM PCI 68 (79.1)
Ostial LM PCI 18 (20.9)
PCI Technique
LM to LAD crossover 42 (48.8)
SKS 8 (9.4)
CULOTTE 4 (4.7)
LM to LCX crossover 8 (9.4)
LM Stenting only 23 (26.7)
IVUS 30 (34.9)
IABP placement 20 (23.3)
TPM placed 14 (16.3)
Inotropic support 19 (22.1)
LM: Left main; LAD: Left anterior descending artery; LCx: Left circumflex artery; PCI: Percutanoeus
coronary intervention; IVUS: Intravascular ultrasound; IABP: Intra aortic balloon pump;
TPM: Temporary pacemaker; SKS: Simultaneous kissing stenting; TPM: Temporary
pacemaker.
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Amongst the 10 patients who had MI, distal LM PCI was
performed in 9 (10.4%) patients with bifurcation stenting
of distal LM done in 4 (4.6%) patients and left main to
LAD crossover was done in 5 (5.8%) patients. Four
(4.6%) patients showed in-stent restenosis (ISR) in left
main stent on subsequent angiograms. All patients
developing ISR had distal LM stenting with LM-LAD
crossover technique applied in two patients and
bifurcation stenting done in two patients. All patients
developing ISR had DES implanted with a mean
diameter of 3.13 ±0.47 mm with post-dilatation
performed with a mean balloon size of 3.0 ±0.40 mm.
DISCUSSION
The treatment of choice for critical left main disease is
CABG. The current guidelines, in light of published
literature, also endorse CABG for LM disease as a class I
recommendation. However, the guidelines also take into
consideration the option of LM PCI an alternative
therapeutic option for left main disease in patients who
are either not suitable for surgical re-vascularisation,13
or decline CABG.
Recent literature shows that PCI is non-inferior to CABG
for the treatment of left main disease.10-15 This success
of PCI to LM is attributed primarily to the introduction of
newer generation DES and the use of dual anti-platelet
therapy. The advent of drug eluting stents has a
significant impact on the outcomes of left main stenting,
as several registries regarding LM stenting with DES
have shown positive results in terms of efficacy and
safety profile.
The present study reported a mortality of 29% at mean
follow-up. This inflated figure could be explained by the
fact that among the cases undergoing LM PCI at our
centre, most of the patients were elderly (mean age 66
±12.5 years), in cardiogenic shock at the time of PCI
(18.6%) and deemed unfit for CABG (23.3%).
Unprotected left main PCI (UPLM PCI) is an option
employed mostly in emergency situations that preclude
an invasive option. Therefore, outcomes are also
affected by the adverse clinical presentation rather than
the procedure itself. Unprotected LM (UPLM) has been
identified as an important predictor of mortality in
previous studies.16-18 In this study, mortality in UPLM
was 23.2%. An explanation for this high rate MACE is
the fact that 81.25% of patients who had UPLM PCI also
had significant disease of a non-LM vessel requiring
intervention. The high occurrence of adverse events in
this group can be attributed to the inherent heavy
atherosclerotic burden.
The mortality of distal LM PCI was 23.2% (20 patients)
with ISR seen in 4.5% of patients undergoing repeat
angiograms. This experience of distal LM PCI was
comparable to the reported literature that suggests that
PCI of lesions involving the ostium or shaft of LM are
associated with better outcomes.19,20 Similarly, studies
have reflected that PCI for distal LM lesions is the most
significant predictor of repeat revascularisation and
overall MACE.21 The high mortality among distal LM PCI
patients can be attributed to the complex anatomy of
distal LM.
The usage of smaller size stents in the left main may be
attributed to diffuse disease in left main system.
However, as there exists no reference values from our
population on minimal surface area (MSA) and minimal
luminal diameter of left main, subjective assessment of
the operators emerges as the plausible rationale for this
discrepancy. Although it has been recognised in the
EXCEL trial that a small final MSA measured by IVUS
after LM-PCI has a strong association with adverse
events during long-term follow-up.22
The main limitation of this study is its retrospective
design. As all the patients did not have angiographic
follow-up, the true rate of restenosis of LM could not be
determined. Thirteen patients were lost to follow-up and
no data could be retrieved for these patients.
CONCLUSION
Though CABG is the preferred choice of treatment for
LM lesions, PCI of left main coronary artery is an option
primarily reserved for those patients who require urgent
revascularisation due to hemodynamic instability. Due to
the anatomical location of LM lesions and the complexity
of PCI in left main, there is a significant chance of
restenosis. Planned, and elective PCI of LM lesions
performed under IVUS guidance have better outcomes,
with reduced rates of restenosis and MACE. Further
prospective studies are required to evaluate the role of
PCI for LM lesions in elective setting.
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